流行病学研究中银屑病与性功能障碍及勃起功能障碍的关联:系统综述
该系统综述检索了截至2017年8月25日的文献,纳入28项研究(52 520例银屑病病例和1 806 022例对照),评估银屑病与性功能障碍(SD)及勃起功能障碍(ED)的流行病学关联和治疗结局。性功能障碍患病率为40.0%至55.6%,勃起功能障碍患病率为34.2%至81.1%。在银屑病患者中,焦虑和抑郁、银屑病关节炎、生殖器银屑病与性功能障碍关联最强;生物制剂治疗可改善性功能障碍。
要点
- 银屑病患者中性功能障碍和勃起功能障碍患病率较高,分别为40.0%-55.6%和34.2%-81.1%。
- 焦虑、抑郁、银屑病关节炎、生殖器皮损及年龄增长与性功能障碍风险升高相关。
- 生物制剂临床试验显示可改善银屑病患者的性功能障碍。
核心结论
- 银屑病患者存在与性功能障碍风险升高相关的生理和心理共病,银屑病本身可能在其发生中起作用。
- 焦虑、抑郁、银屑病关节炎、生殖器皮损和年龄增长应提高对性功能障碍的警觉。
- 生物制剂已被证明可改善银屑病患者的性功能障碍。
研究设计与样本
- 系统综述,检索MEDLINE和Embase数据库(通过Scopus搜索引擎),检索时间为2017年8月25日。
- 纳入28项研究,包括19项横断面研究、3项临床试验、3项类实验研究、2项基于人群的队列研究和1项基于人群的病例对照研究。
- 共纳入52 520例银屑病病例和1 806 022例对照。
- 证据质量根据牛津循证医学中心(Centre for Evidence-Based Medicine)标准评估。
主要发现
- 性功能障碍患病率范围为40.0%至55.6%,勃起功能障碍患病率范围为34.2%至81.1%。
- 2项研究在调整生理和心理共病后均观察到银屑病与性功能障碍的关联。
- 8项研究中有5项观察到勃起功能障碍与银屑病的独立关联。
- 在银屑病患者中,与性功能障碍关联最强的特征是焦虑和抑郁(5项研究全部)、银屑病关节炎(4项中3项)和生殖器银屑病(7项中5项)。
- 关于勃起功能障碍,焦虑和抑郁(2项研究全部)和年龄增长(3项研究全部)显示最强关联;3项使用生物制剂的临床试验均显示与安慰剂相比性功能障碍改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Sexual health is a major aspect of life. Increasing scientific evidence shows a potential association between psoriasis and sexual dysfunction (SD) and erectile dysfunction (ED). OBJECTIVE: To evaluate the available scientific evidence regarding epidemiologic associations and treatment outcomes between psoriasis and SD and ED. EVIDENCE REVIEW: Information sources were MEDLINE and Embase databases, using the Scopus search engine. The search was performed on August 25, 2017. Search terms were psoriasis and sexual or sexual dysfunction, and the search was limited to epidemiologic studies published in English answering any of the 4 research questions. Quality was assessed according to the Centre for Evidence-Based Medicine. FINDINGS: Twenty-eight studies representing 52 520 cases of psoriasis and 1 806 022 controls were included for review. Of the 28 studies, 19 were cross-sectional, 3 were clinical trials, 3 were quasi-experimental, 2 were population-based cohort, and 1 was population-based case-control. Prevalence of SD and ED ranged from 40.0% to 55.6% and 34.2% to 81.1%, respectively. Two of 2 studies observed an association between psoriasis and SD after adjusting for physical and psychological comorbidities. Five of 8 studies observed an independent association between ED and psoriasis. Among patients with psoriasis, the features that showed the strongest association with SD were anxiety and depression (5 of 5 studies), psoriatic arthritis (3 of 4 studies), and genital psoriasis (5 of 7 studies). Regarding ED, anxiety and depression (2 of 2 studies) and increasing age (3 of 3 studies) showed the strongest association. All 3 clinical trials using biologic drugs showed an improvement in SD compared with placebo. CONCLUSIONS AND RELEVANCE: Patients with psoriasis have physical and psychological comorbidities that have been associated with a higher risk of SD. In addition, psoriasis may play a role in its development. The presence of anxiety, depression, psoriatic arthritis, genital lesions, and increasing age should raise the awareness of SD. Biologic drugs have demonstrated the improvement of SD in patients with psoriasis.
引用
- Molina-Leyva A, Salvador-Rodriguez L, Martinez-Lopez A, et al. Association Between Psoriasis and Sexual and Erectile Dysfunction in Epidemiologic Studies: A Systematic Review. JAMA Dermatol. 2019. PMID: 30304327. doi:10.1001/jamadermatol.2018.3442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。